Ipca Labs board approves merger of Krebs Biochemicals

Scheme filed with the NCLTStrategic Transactions View source PDF Explain this filing

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹1619.90

prior close

₹1618.30

announcement price

After-mkt

timing

Nifty Midcap 150market-0.3%+1.7% vs market

Pharmaceuticals peers, median of 165sector+0.1%+1.3% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Midcap 150 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+0.8

15m

+1.2

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4-0.3+1.7+0.1+1.3

Next day

+5.4+0.1+5.3+0.9+4.5

+4.8+0.3+4.4+0.3+4.4

+6.3+0.8+5.5+0.8+5.5

+9.6+0.6+9.0+1.7+7.8

+9.9+1.0+8.9+1.5+8.4

+8.9-0.9+9.8+0.1+8.8

15d

+13.0+1.5+11.5+1.8+11.2

+9.6+1.6+8.0+1.6+8.1

+21.7+3.5+18.3+1.1+20.6

+20.4-3.9+24.3+4.6+15.8

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ipca Labs board approved merger of Krebs Biochemicals & Industries into itself under a scheme of amalgamation. No cash consideration; share swap ratio is 7 Ipca shares of Re.1 each for every 200 Krebs shares of Rs.10 each. Ipca FY26 total income was Rs.7,431 crore versus Krebs at Rs.26 crore. Krebs makes fermentation-based APIs that Ipca currently sources from it, so the deal secures supply. It is a related party transaction done at arm's length. Promoter holding will dip marginally from 44.72% to 44.66%.

Likely market impact

Small related-party merger secures critical API supply chain with minimal dilution. No open offer triggered. Promoter stake dips marginally.